Targeted therapies against MET remain an active area of investigation in oncology research and drug development with numerous clinical trials of MET inhibitors ongoing for MET-aberrant cancers (Yang et al., 2023; Mazieres et al., 2023a). The gene discussed is MET; the disease is cancer.